Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

bioxcel therapeutics inc - BTAI

BTAI

Close Chg Chg %
0.12 -0.04 -37.11%

Closed Market

0.07

-0.04 (37.11%)

Volume: 47.48M

Last Updated:

Sep 4, 2026, 4:00 PM EDT

Trade Now

Company Overview: bioxcel therapeutics inc - BTAI

BTAI Key Data

Open

$0.09

 Day Range

0.07 - 0.09

52 Week Range

0.07 - 4.29

 Market Cap

$2.19M

Shares Outstanding

31.31M

 Public Float

N/A

Beta

0.19

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$4.23

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

15.17M

  

BTAI Performance

No Data Available

BTAI Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 1
Full Ratings ➔
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Bioxcel Therapeutics Inc - BTAI

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
375.00K 1.38M 2.27M 642.00K
Sales Growth
- +268.00% +64.20% -71.67%
Cost of Goods Sold (COGS) incl D&A
347.00K 1.58M 2.45M 464.00K
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
327.00K 318.00K 309.00K 300.00K
Depreciation
327.00K 318.00K 309.00K 300.00K
Amortization of Intangibles
- - - -
-
COGS Growth
+16.84% +354.76% +55.39% -81.08%
Gross Income
28.00K (198.00K) (186.00K) 178.00K
Gross Income Growth
+109.43% -807.14% +6.06% +195.70%
Gross Profit Margin
+7.47% -14.35% -8.21% +27.73%
2022 2023 2024 2025 5-year trend
SG&A Expense
158.44M 166.13M 63.29M 49.88M
Research & Development
89.93M 82.93M 29.19M 29.48M
Other SG&A
68.51M 83.20M 34.10M 20.41M
SGA Growth
+50.04% +4.86% -61.91% -21.18%
Other Operating Expense
- - - -
-
Unusual Expense
1.83M 5.01M 3.17M 9.79M
EBIT after Unusual Expense
(160.24M) (171.34M) (66.64M) (59.49M)
Non Operating Income/Expense
2.53M 5.61M 22.17M 6.58M
Non-Operating Interest Income
2.53M 5.65M 2.60M 1.07M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
8.21M 13.31M 15.13M 16.98M
Interest Expense Growth
- +62.11% +13.63% +12.26%
Gross Interest Expense
8.21M 13.31M 15.13M 16.98M
Interest Capitalized
- - - -
-
Pretax Income
(165.92M) (179.05M) (59.60M) (69.90M)
Pretax Income Growth
-54.65% -7.91% +66.71% -17.28%
Pretax Margin
-44,246.40% -12,974.86% -2,630.14% -10,887.38%
Income Tax
- - - (167.00K)
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - 167.00K
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(165.76M) (179.05M) (59.60M) (69.90M)
Minority Interest Expense
- - - -
-
Net Income
(165.76M) (179.05M) (59.60M) (69.90M)
Net Income Growth
-55.01% -8.02% +66.71% -17.28%
Net Margin Growth
-44,201.87% -12,974.86% -2,630.14% -10,887.38%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(165.76M) (179.05M) (59.60M) (69.90M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(165.76M) (179.05M) (59.60M) (69.90M)
EPS (Basic)
-94.6675 -98.3504 -23.5104 -5.7255
EPS (Basic) Growth
-45.93% -3.89% +76.10% +75.65%
Basic Shares Outstanding
1.75M 1.82M 2.54M 12.21M
EPS (Diluted)
-94.6675 -98.3504 -23.5104 -5.7255
EPS (Diluted) Growth
-45.93% -3.89% +76.10% +75.65%
Diluted Shares Outstanding
1.75M 1.82M 2.54M 12.21M
EBITDA
(158.08M) (166.01M) (63.16M) (49.41M)
EBITDA Growth
-49.70% -5.02% +61.95% +21.78%
EBITDA Margin
-42,155.73% -12,030.07% -2,787.51% -7,695.48%

Bioxcel Therapeutics Inc in the News